When considering the tumor stage, the most frequently mutated sites in both the NMIBC subgroup and the MIBC subgroup were the TERT promoter, TP53, ARID1A, and PIK3CA (Figure 4c,d). This evidence concerns the gene TP53 and neoplasm.